4-((2-chloroethyl)(2-mesyloxyethyl)amino)benzoylglutamic acid has been researched along with Angiogenesis, Pathologic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brueggen, J; Friedlos, F; Marais, R; Matter, A; Maycroft, K; O'Reilly, T; Roussel, J; Spooner, RA; Springer, CJ; Stolz, B; Stribbling, SM; Wood, J | 1 |
| Begent, RH; Boden, R; Boxer, GM; Davies, L; Pedley, RB; Sharma, SK; Springer, CJ; Stribbling, SM | 1 |
2 other study(ies) available for 4-((2-chloroethyl)(2-mesyloxyethyl)amino)benzoylglutamic acid and Angiogenesis, Pathologic
| Article | Year |
|---|---|
A novel vascular endothelial growth factor-directed therapy that selectively activates cytotoxic prodrugs.
Topics: Adenocarcinoma; Endothelial Growth Factors; Endothelium; Female; gamma-Glutamyl Hydrolase; Glutamates; Glutamine; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mutagenesis, Site-Directed; Neovascularization, Pathologic; Nitrogen Mustard Compounds; Ovarian Neoplasms; Plasmids; Point Mutation; Prodrugs; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2003 |
Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
Topics: Animals; Antineoplastic Agents; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; gamma-Glutamyl Hydrolase; Glutamates; Humans; Immunoconjugates; Immunoglobulin Fab Fragments; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Nitrogen Mustard Compounds; Prodrugs; Transplantation, Heterologous; Xanthenes; Xanthones | 1999 |